Hypersensitivity reactions including anaphylaxis and angioedema have occurred in patients receiving etoricoxib; it should be stopped at the first signs of hypersensitivity. Etoricoxib should be avoided in patients with severe hepatic impairment. Therapy should be stopped if persistently abnormal liver enzyme values are seen. Etoricoxib should not be used in patients with ischemic heart disease, peripheral arterial disease or cerebrovascular disease.